Humana Total increased by 9.2% to $18.59B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.3%, from $19.43B to $18.59B. Over 3 years (FY 2022 to FY 2025), Total shows relatively stable performance with a 2.2% CAGR.
Changes reflect the scale of the investment portfolio and the firm's capital deployment strategy into debt instruments.
This represents the original cost of debt securities classified as available-for-sale, adjusted for amortization of prem...
Standard metric for financial institutions and insurance companies holding fixed-income portfolios.
other_available_for_sale_debt_securities_amortized_cost_basis| Q4 '22 | Q1 '23 | Q2 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.95B | $16.75B | $17.23B | $18.30B | $18.49B | $19.27B | $20.28B | $20.02B | $19.43B | $19.11B | $18.04B | $17.02B | $18.59B |
| QoQ Change | — | +5.0% | +2.9% | +6.2% | +1.0% | +4.2% | +5.3% | -1.3% | -3.0% | -1.6% | -5.6% | -5.7% | +9.2% |
| YoY Change | — | — | — | +14.8% | +10.4% | +11.8% | — | +9.4% | +5.1% | -0.8% | -11.0% | -15.0% | -4.3% |